

# Gatien Moriceau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050492/publications.pdf>

Version: 2024-02-01

13  
papers

2,863  
citations

759233

12  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

4629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasticity of Extrachromosomal and Intrachromosomal <i>BRAF</i> Amplifications in Overcoming Targeted Therapy Dosage Challenges. <i>Cancer Discovery</i> , 2022, 12, 1046-1069.	9.4	27
2	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. <i>Cancer Discovery</i> , 2022, 12, 1942-1959.	9.4	15
3	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. <i>Cancer Discovery</i> , 2021, 11, 714-735.	9.4	45
4	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021, 39, 1375-1387.e6.	16.8	78
5	<i>SPRED1</i> deletion confers resistance to MAPK inhibition in melanoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	19
6	Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. <i>Cancer Discovery</i> , 2018, 8, 74-93.	9.4	89
7	Recurrent Tumor Cell "Intrinsic and "Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. <i>Cancer Discovery</i> , 2017, 7, 1248-1265.	9.4	134
8	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. <i>Journal of Translational Medicine</i> , 2015, 13, 210.	4.4	97
9	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	16.8	299
10	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. <i>Cell</i> , 2015, 162, 1271-1285.	28.9	516
11	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	9.4	141
12	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2014, 4, 80-93.	9.4	836
13	Melanoma whole-exome sequencing identifies V600E-BRAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	12.8	567